COMP <GO>
GMED vs PODD // RETURN ON INVESTED CAPITAL (ROIC)
Globus Medical Inc. (NYSE) VS. Insulet Corporation (NASDAQ) • 15-METRIC TALLY: GMED 7
— PODD 6
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: PODD
LAST: $78.05 (-5.86%) • MKT CAP: $10.48B
roic
8.70%
LAST: $149.68 (-1.85%) • MKT CAP: $10.38B
roic
20.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GMED VS. PODD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GMED | PODD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 67.40% | 71.60% | -4.20 | PODD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 8.70% | 20.40% | -11.70 | PODD | /roic <GO> |
| EV/EBITDA & P/E Valuation | 17.6x | 17.1x | +0.50 | PODD | /valuation <GO> |
| Free Cash Flow Yield | 5.29% | 3.57% | +1.72 | GMED | /fcf-yield <GO> |
| Operating Margin | 16.30% | 17.50% | -1.20 | PODD | /operating-margins <GO> |
| Net Profit Margin | 18.30% | 9.10% | +9.20 | GMED | /net-margins <GO> |
| Revenue Growth (YoY) | 16.70% | 30.70% | -14.00 | PODD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 10.74 | 5.72 | +5.02 | GMED | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | GMED | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.0 | 59.3 | -11.30 | PODD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 0.99 | +0.08 | GMED | /macro-sensitivity <GO> |
| Forward P/E Multiple | 17.4x | 36.0x | -18.60 | GMED | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.48B | $10.38B | $98.2M | GMED | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GMED REV | PODD REV | GMED GROSS % | PODD GROSS % | GMED FCF | PODD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.94B | $2.71B | 67.4% | 71.6% | $588.8M | $377.7M |
| FY 2024 | $2.52B | $2.07B | 58.9% | 69.8% | $405.2M | $305.3M |
| FY 2023 | $1.57B | $1.70B | — | — | $172.9M | $69.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GMED // BETA 1.07
PODD // BETA 0.99